vs
MESA LABORATORIES INC（MLAB）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是READING INTERNATIONAL INC的1.3倍（$65.1M vs $50.3M），MESA LABORATORIES INC净利率更高（5.6% vs -5.1%，领先10.7%），MESA LABORATORIES INC同比增速更快（3.6% vs -14.2%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $4.1M），过去两年READING INTERNATIONAL INC的营收复合增速更高（5.6% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
MLAB vs RDI — 直观对比
营收规模更大
MLAB
是对方的1.3倍
$50.3M
营收增速更快
MLAB
高出17.8%
-14.2%
净利率更高
MLAB
高出10.7%
-5.1%
自由现金流更多
MLAB
多$13.9M
$4.1M
两年增速更快
RDI
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $50.3M |
| 净利润 | $3.6M | $-2.6M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | -1.9% |
| 净利率 | 5.6% | -5.1% |
| 营收同比 | 3.6% | -14.2% |
| 净利润同比 | 316.6% | -14.5% |
| 每股收益（稀释后） | $0.65 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRDI
| Q4 25 | $65.1M | $50.3M | ||
| Q3 25 | $60.7M | $52.2M | ||
| Q2 25 | $59.5M | $60.4M | ||
| Q1 25 | $62.1M | $40.2M | ||
| Q4 24 | $62.8M | $58.6M | ||
| Q3 24 | $57.8M | $60.1M | ||
| Q2 24 | $58.2M | $46.8M | ||
| Q1 24 | $58.9M | $45.1M |
净利润MLABRDI
| Q4 25 | $3.6M | $-2.6M | ||
| Q3 25 | $2.5M | $-4.2M | ||
| Q2 25 | $4.7M | $-2.7M | ||
| Q1 25 | $-7.1M | $-4.8M | ||
| Q4 24 | $-1.7M | $-2.2M | ||
| Q3 24 | $3.4M | $-7.0M | ||
| Q2 24 | $3.4M | $-12.8M | ||
| Q1 24 | $-254.6M | $-13.2M |
毛利率MLABRDI
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABRDI
| Q4 25 | 12.2% | -1.9% | ||
| Q3 25 | 7.8% | -0.6% | ||
| Q2 25 | 5.1% | 4.8% | ||
| Q1 25 | 2.4% | -17.2% | ||
| Q4 24 | 9.2% | 2.6% | ||
| Q3 24 | 6.1% | -0.6% | ||
| Q2 24 | 9.6% | -16.4% | ||
| Q1 24 | -460.6% | -16.7% |
净利率MLABRDI
| Q4 25 | 5.6% | -5.1% | ||
| Q3 25 | 4.1% | -8.0% | ||
| Q2 25 | 8.0% | -4.4% | ||
| Q1 25 | -11.4% | -11.8% | ||
| Q4 24 | -2.7% | -3.8% | ||
| Q3 24 | 5.9% | -11.7% | ||
| Q2 24 | 5.8% | -27.4% | ||
| Q1 24 | -432.2% | -29.4% |
每股收益（稀释后）MLABRDI
| Q4 25 | $0.65 | $-0.11 | ||
| Q3 25 | $0.45 | $-0.18 | ||
| Q2 25 | $0.85 | $-0.12 | ||
| Q1 25 | $-1.30 | $-0.21 | ||
| Q4 24 | $-0.31 | $-0.11 | ||
| Q3 24 | $0.63 | $-0.31 | ||
| Q2 24 | $0.62 | $-0.57 | ||
| Q1 24 | $-47.26 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $10.5M |
| 总债务越低越好 | $68.4M | $185.1M |
| 股东权益账面价值 | $186.7M | $-18.2M |
| 总资产 | $434.8M | $434.9M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABRDI
| Q4 25 | $29.0M | $10.5M | ||
| Q3 25 | $20.4M | $8.1M | ||
| Q2 25 | $21.3M | $9.1M | ||
| Q1 25 | $27.3M | $5.9M | ||
| Q4 24 | $27.3M | $12.4M | ||
| Q3 24 | $24.3M | $10.1M | ||
| Q2 24 | $28.5M | $9.3M | ||
| Q1 24 | $28.2M | $7.5M |
总债务MLABRDI
| Q4 25 | $68.4M | $185.1M | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | $202.7M | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABRDI
| Q4 25 | $186.7M | $-18.2M | ||
| Q3 25 | $178.5M | $-12.1M | ||
| Q2 25 | $172.5M | $-7.7M | ||
| Q1 25 | $159.8M | $-8.1M | ||
| Q4 24 | $155.2M | $-4.4M | ||
| Q3 24 | $161.5M | $1.6M | ||
| Q2 24 | $150.7M | $6.5M | ||
| Q1 24 | $145.4M | $18.0M |
总资产MLABRDI
| Q4 25 | $434.8M | $434.9M | ||
| Q3 25 | $430.4M | $435.2M | ||
| Q2 25 | $435.7M | $438.1M | ||
| Q1 25 | $433.3M | $441.0M | ||
| Q4 24 | $433.3M | $471.0M | ||
| Q3 24 | $454.1M | $495.7M | ||
| Q2 24 | $440.4M | $494.9M | ||
| Q1 24 | $446.8M | $494.9M |
负债/权益比MLABRDI
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $4.1M |
| 自由现金流率自由现金流/营收 | 27.7% | 8.2% |
| 资本支出强度资本支出/营收 | 1.1% | 0.3% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流MLABRDI
| Q4 25 | $18.8M | $4.3M | ||
| Q3 25 | $8.2M | $295.0K | ||
| Q2 25 | $1.9M | $1.6M | ||
| Q1 25 | $12.7M | $-7.7M | ||
| Q4 24 | $18.1M | $8.0M | ||
| Q3 24 | $5.3M | $1.3M | ||
| Q2 24 | $10.7M | $-10.4M | ||
| Q1 24 | $12.9M | $-2.8M |
自由现金流MLABRDI
| Q4 25 | $18.0M | $4.1M | ||
| Q3 25 | $7.1M | $-246.0K | ||
| Q2 25 | $884.0K | $1.2M | ||
| Q1 25 | $11.9M | $-8.0M | ||
| Q4 24 | $17.3M | $7.0M | ||
| Q3 24 | $3.5M | $-1.1M | ||
| Q2 24 | $9.9M | $-10.6M | ||
| Q1 24 | $12.3M | $-4.7M |
自由现金流率MLABRDI
| Q4 25 | 27.7% | 8.2% | ||
| Q3 25 | 11.7% | -0.5% | ||
| Q2 25 | 1.5% | 1.9% | ||
| Q1 25 | 19.2% | -19.8% | ||
| Q4 24 | 27.6% | 12.0% | ||
| Q3 24 | 6.0% | -1.8% | ||
| Q2 24 | 16.9% | -22.7% | ||
| Q1 24 | 21.0% | -10.4% |
资本支出强度MLABRDI
| Q4 25 | 1.1% | 0.3% | ||
| Q3 25 | 1.8% | 1.0% | ||
| Q2 25 | 1.7% | 0.6% | ||
| Q1 25 | 1.2% | 0.6% | ||
| Q4 24 | 1.3% | 1.7% | ||
| Q3 24 | 3.1% | 4.0% | ||
| Q2 24 | 1.5% | 0.5% | ||
| Q1 24 | 0.9% | 4.3% |
现金转化率MLABRDI
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
